---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-097206"
form_type: "8-K"
ticker: "ELDN"
cik: "0001404281"
company_name: "Eledon Pharmaceuticals, Inc."
filed_at: "2024-08-14T23:59:59+00:00"
generated_at: "2026-05-31T09:17:06.650141+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Eledon restates financials due to warrant misclassification; reports $83.6M cash and Phase 2 progress

## Summary
- Non-reliance on FY2023 and Q1 2024 financials due to warrant derivative accounting error; expects restatement and amendments.
- Ended Q2 with $83.6M cash, including $50M private placement; expects liquidity through December 2025.
- Phase 2 BESTOW trial enrolled 80th participant, on track to complete enrollment by end of 2024.
- Phase 1b data from 13 kidney transplant patients showed mean eGFR 70.5; two patients >90 at one year.
- Identified material weakness in internal control over financial reporting; restatement is non-cash and does not affect operations.

## SEC filing metadata
- accession: 0000950170-24-097206
- form_type: 8-K
- ticker: ELDN
- cik: 0001404281
- company_name: Eledon Pharmaceuticals, Inc.
- filed_at: 2024-08-14T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 4.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1404281/000095017024097206/0000950170-24-097206-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1404281/000095017024097206/eldn-20240814.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-097206
- JSON: https://secwatch.observer/filing/0000950170-24-097206.json
- Plain text: https://secwatch.observer/filing/0000950170-24-097206.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.